Gilead Sciences GILD
NASDAQ GILD
$146.12 +2.68 (+1.87%)
At close: Aug 21, 2026 · 4:00 PM EDT

Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026)

Gilead Sciences' (GILD) quarterly Goodwill & Intangibles came in at $24.7 billion in Q1 2026, down 10.74% YoY from $27.7 billion in Q1 2025, and down 2.36% on a QoQ basis from $25.3 billion in Q4 2025.

Gilead Sciences (GILD) Goodwill & Intangibles (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has 18 years of Goodwill & Intangibles data on file, last reported at $24.7 billion in Q1 2026.

  • Quarterly Goodwill & Intangibles fell 10.74% year-over-year to $24.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 billion (down 10.74% YoY) and the FY2025 annual result came in at $25.3 billion, down 10.51% from the prior year.
  • Goodwill & Intangibles retreated to $24.7 billion in Q1 2026, from $25.3 billion in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $38.6 billion in Q1 2022 to a low of $24.7 billion in Q1 2026.
  • A 5-year average of $32.1 billion and a median of $31.7 billion in 2024 frame the typical range for Goodwill & Intangibles.
  • Annual changes were most pronounced in 2023 — Goodwill & Intangibles decreased 5.13% — and 2024, when it declined 18.71%.
  • Tracing GILD's Goodwill & Intangibles over 5 years: stood at $37.2 billion in 2022, then declined by 6.56% to $34.8 billion in 2023, then decreased by 18.71% to $28.3 billion in 2024, then decreased by 10.51% to $25.3 billion in 2025, then decreased by 2.36% to $24.7 billion in 2026.
  • The last three Goodwill & Intangibles figures came in at $24.7 billion (Q1 2026), $25.3 billion (Q4 2025), and $26.3 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Sanofi 55.07 Bn 47.69 Bn 10.79 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 22.35 Bn
Mar 31, 2026 24.70 Bn
Dec 31, 2025 25.29 Bn
Sep 30, 2025 26.28 Bn
Jun 30, 2025 26.88 Bn
Mar 31, 2025 27.67 Bn
Dec 31, 2024 28.26 Bn
Sep 30, 2024 28.86 Bn
Jun 30, 2024 31.15 Bn
Mar 31, 2024 31.74 Bn
Dec 31, 2023 34.77 Bn
Sep 30, 2023 35.47 Bn
Jun 30, 2023 36.06 Bn
Mar 31, 2023 36.66 Bn
Dec 31, 2022 37.21 Bn
Sep 30, 2022 37.75 Bn
Jun 30, 2022 38.20 Bn
Mar 31, 2022 38.65 Bn
Dec 31, 2021 41.79 Bn
Sep 30, 2021 42.23 Bn